Editas Medicine (EDIT) vs Entera Bio (ENTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Entera Bio (ENTX) has outperformed Editas Medicine (EDIT) over the past year, gaining 32.8% versus a loss of 30.0%. Over five years, ENTX leads with a -44.5% price change compared with -92.8% for EDIT. Editas Medicine is the larger company by market cap ($436.2 million vs $428.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | ENTX |
|---|---|---|
| Share price | $2.84 | $2.47 |
| Market cap | $436.17M | $428.50M |
| 1-day change | +3.27% | -1.79% |
| YTD return | +34.15% | +29.38% |
| 1-year return | -30.03% | +32.80% |
| 5-year return | -92.77% | -44.47% |
| EPS (TTM) | $-0.68 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $4.20 |
| 52-week low | $1.66 | $0.91 |
| Distance from 52-week high | -34.41% | -41.31% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +107.75% | +295.54% |
| Average volume | 2.47M | 1.82M |
| Shares outstanding | 153.58M | 173.83M |
| Employees | 87 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed EDIT by 62.8 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
EDIT vs ENTX FAQ
Which is bigger, Editas Medicine or Entera Bio?
Editas Medicine (EDIT) is larger, with a market capitalization of $436.17M compared with $428.50M for Entera Bio (ENTX).
Which stock has performed better over the past year, EDIT or ENTX?
ENTX returned +32.80% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Entera Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.